Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial
Nutrients 2021, 13(7), 2170; https://doi.org/10.3390/nu13072170
by Shaun Sabico 1OrcID,Mushira A. Enani 2,Eman Sheshah 3,Naji J. Aljohani 1,4,Dara A. Aldisi 5,Naif H. Alotaibi 6,Naemah Alshingetti 7,Suliman Y. Alomar 8OrcID,Abdullah M. Alnaami 1,Osama E. Amer 1OrcID,Syed D. Hussain 1 and Nasser M. Al-Daghri 1,*OrcID
5,000 IU statistically reduced only 2 of 11 mild symptoms
Note: Ageusia is associated with loss of taste
Vitamin D 21 ng ==> 25 ng
COVID-19 treated by Vitamin D - studies, reports, videos
- As of Oct 8, 2021, the page had: 34 trials, 6 trial results, 25 meta-analyses and reviews, 64 observations, 35 recommendations, 55 associations, 89 speculations, 48 videos see related: Governments, HealthProblems, Hospitals, Dark Skins, 26 risk factors are ALL associated with low Vit D, Recent Virus pages Fight COVID-19 with 50K Vit D weekly Vaccines
Note: >70% of the RCT using Vitamin D to fight COVID-19 were using at least 100,000 IU during the first week
The founder of Vitamin D Life had predicted very little success in RCTs using less
Note: Clincal trials in hospitals using much higher doses of Vitamin D have found far better results
Also: Those people who had been taking a good amount of vitamin D before COVID were
1) Less likely to get infected
2) Less likely to need to go to hospital
3) Less likely to have severe COVID-19
4) Less likely to die of COVID-19
Items in both categories Virus and Intervention:
- Vitamin D trial for COVID-19 – using their patented slow-release form – Aug 2021
- COVID-19 mortality reduced 4X (chart looks like 2X) by large, infrequent doses of Vitamin D in France – July 2021
- 5,000 U daily raised Vitamin D a bit and helped COVID-19 a bit – RCT June 2021
- COVID-19 inflammation extinguished by 60,000 IU of vitamin D nanoemulsion daily for a week – RCT May 2021
- Better response to shingles virus test after Vitamin D raised above 40 ng – Jan 2021
- Kidney patients who happened to be getting high-dose Calcitriol were 9X less likely to die of COVID-19 - April 6, 2021
- 5X less likely to enter ICU with COVID-19 if get Calcifediol (semi-activated vitamin D) - RCT Feb 19, 2021
- calcifediol rct
- Swine flu not prevented by 2,000 IU of vitamin D daily (the upper limit at the time) – RCT 2014
- Vaccine antibody generation not change with Vitamin D – 21 ng or 44 ng – RCT Feb 2019
- Dengue virus prevented by a small amount of Vitamin D – RCT Nov 2019
- Half the risk of Influenza -A in infants taking 1200 IU of vitamin D for 4 months – RCT Jan 2018
- Chikungunya virus arthritis pain reduced by weekly 60,000 IU vitamin D – Sept 2016
- Many Infectious diseases (virus) treated and prevented by Vitamin D – review July 2009
- Influenza prevented by 40 ng levels or treated with vitamin D hammer (50,000 IU) – June 2015
- Infection fighting ability increased with 5,000 IU Vitamin D daily – April 2015
- Vitamin D prevents Hepatitis-C and helps treat it (many studies)
- Malaria in mice brains, and associated inflammation, prevented by Vitamin D intervention – July 2014
- Influenza A: 5X reduction in first month (only) with 2,000 IU of vitamin D– RCT July 2014
Download the PDF from Vitamin D Life
Objective: Vitamin D deficiency has been associated with an increased risk of COVID-19 severity. This multi-center randomized clinical trial aims to determine the effects of 5000 IU versus 1000 IU daily oral vitamin D3 supplementation in the recovery of symptoms and other clinical parameters among mild to moderate COVID-19 patients with sub-optimal vitamin D status. Study
Design and Setting: A total of 69 reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive adults who were hospitalized for mild to moderate COVID-19 disease were allocated to receive once daily for 2 weeks either 5000 IU oral vitamin D3 (n = 36, 21 males; 15 females) or 1000 IU oral vitamin D3 (standard control) (n = 33, 13 males; 20 females). Anthropometrics were measured and blood samples were taken pre- and post-supplementation. Fasting blood glucose, lipids, serum 25(OH)D, and inflammatory markers were measured. COVID-19 symptoms were noted on admission and monitored until full recovery.
Results: Vitamin D supplementation for 2 weeks caused a significant increase in serum 25(OH)D levels in the 5000 IU group only (adjusted p = 0.003). Within-group comparisons also showed a significant decrease in BMI and IL-6 levels overtime in both groups (p-values < 0.05) but was not clinically significant in between-group comparisons. Kaplan–Meier survival analysis revealed that the 5000 IU group had a significantly shorter time to recovery (days) than the 1000 IU group in resolving cough, even after adjusting for age, sex, baseline BMI, and D-dimer (6.2 ± 0.8 versus 9.1 ± 0.8; p = 0.039), and ageusia (loss of taste) (11.4 ± 1.0 versus 16.9 ± 1.7; p = 0.035).
Conclusion: A 5000 IU daily oral vitamin D3 supplementation for 2 weeks reduces the time to recovery for cough and gustatory sensory loss among patients with sub-optimal vitamin D status and mild to moderate COVID-19 symptoms. The use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19 patients with suboptimal vitamin D status, even for a short duration, is recommended.